Introduction to
Biomarker-Screened FFPE Specimens
Buy FFPE Biomarker -Screened Specimens for Oncology Research
FFPE biomarker-screened specimens provide preserved tumour tissue that has been evaluated for one or more molecular or protein markers. Screening may involve IHC, FISH, ISH, PCR, NGS or another validated or research-grade method. Depending on the project, researchers may request specimens positive or negative for markers such as PD-L1, HER2, ER, PR, Ki-67, EGFR, ALK, ROS1, MSI or selected mutations. The screening report should identify the assay, platform, clone or probe, scoring method, cut-off and result. Researchers should avoid treating biomarker results as interchangeable when different assays or interpretation systems were used.
Pathology review should confirm diagnosis, tumour percentage, necrosis and remaining material. Clinical annotations may include stage, grade, treatment exposure and outcomes where available. Properly documented and ethically sourced FFPE biomarker-screened specimens can reduce prescreening time and support oncology research, assay development, drug discovery and biomarker-validation programmes.
FFPE Biomarker -Screened Specimens With Clinical Annotations
FFPE biomarker-screened specimens with clinical annotations combine tissue-based test results with pathological and patient-level information. Available annotations may include age, sex, diagnosis, histological subtype, stage, grade, specimen site, treatment history, response and follow-up. These integrated specimens can support studies examining associations between biomarker status, disease characteristics and clinical outcomes. Researchers should define required clinical fields and acceptable missing-data limits before cohort selection.
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
Source Quality -Controlled Biomarker-Positive FFPE Samples
Quality-controlled biomarker-positive FFPE samples can be sourced using specific pathology, assay and scoring criteria. Researchers should state the cancer indication, biomarker, test method, positivity threshold, specimen type, tumour percentage and required tissue quantity. For IHC biomarkers, the request may need to specify the antibody clone, staining platform and scoring approach. For genomic biomarkers, the sequencing or PCR method, detected alteration and supporting quality metrics should be documented. A recent H&E review can confirm diagnosis, representative tumour, necrosis and available material.
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
FFPE Biomarker -Screened Specimens for Precision Medicine
FFPE biomarker-screened specimens can support precision-medicine research by enabling investigators to study tumours grouped according to molecular or protein characteristics. Samples may be selected using actionable mutations, gene fusions, amplifications, receptor expression, immune markers or genomic signatures. Researchers can use the remaining tissue to investigate treatment targets, resistance mechanisms, tumour heterogeneity and interactions within the tumour microenvironment. Biomarker interpretation must account for the original assay, scoring method, threshold and cancer indication. A result considered positive in one clinical context may not have the same meaning in another. Pathology review should confirm tissue suitability, while clinical annotations can provide information about therapies and outcomes where available. Biomarker-positive and biomarker-negative groups should be balanced for relevant confounding variables. Properly curated FFPE biomarker-screened specimens can facilitate hypothesis generation, assay comparison and retrospective precision-oncology studies without implying direct clinical utility.
Molecularly Tested FFPE Specimens for Biomarker Studies
Molecularly tested FFPE specimens provide researchers with tissue linked to results from PCR, NGS, FISH, ISH or other molecular methods. These specimens can be used to investigate new biomarkers, compare testing technologies and examine relationships between genomic alterations and tissue-based findings. Researchers may request cases with specific mutations, amplifications, deletions, fusions, microsatellite instability or other molecular features. The supporting report should identify the platform, assay version, genes or regions assessed, result interpretation and available quality metrics. Negative controls must have adequate assay coverage of the target alteration. Pathology review can confirm diagnosis, tumour percentage, necrosis and areas suitable for analysis. Clinical annotations may add value when biomarker status is being compared with treatment or outcome. Researchers should control for fixation, block age and collection site to reduce technical bias. Carefully selected molecularly tested FFPE specimens can support exploratory biomarker discovery and subsequent analytical-validation studies.
Order Clinically Annotated FFPE Biomarker- Screened Specimens
Clinically annotated FFPE biomarker-screened specimens can be ordered according to customised disease, assay, tissue and data criteria. Researchers should specify the tumour type, histological subtype, stage, specimen site, biomarker, testing platform, scoring system and required positivity range. Mandatory clinical fields—such as treatment, response, progression or follow-up—should be identified before sourcing. A preliminary manifest may include pathology findings, biomarker results, test methodology and available de-identified clinical information. Pathology quality control should verify diagnosis, tumour percentage, necrosis and remaining material. Researchers may also request H&E images, unstained sections, tissue curls or repeat biomarker testing. All specimens and associated data should be collected, processed and transferred under appropriate consent, ethics, privacy and contractual requirements. A project-specific procurement process helps create consistent positive, negative or score-stratified cohorts for pharmaceutical, biotechnology and academic research.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.